Clinical situations arise in which blood for transfusion becomes scarce or unavailable. Considerable demand for a transfusion alternative persists because of various difficulties posed by blood donation and transfusion systems.
Hemoglobin-vesicles (Hb- V) are artificial
oxygen carriers being developed for use as a transfusion alternative. Just as biomembranes of red blood cells (RBCs) do,
phospholipid vesicles (
liposomes) for Hb encapsulation can protect the human body from the toxic effects of molecular Hb. The main HbV component, Hb, is obtained from discarded human donated blood. Therefore, HbV can be categorized as a biologic agent targeting
oxygen for peripheral tissues. The purification procedure strictly eliminates the possibility of viral contamination. It also removes all concomitant unstable
enzymes present in RBC for utmost safety from
infection. The deoxygenated HbVs, which are storable for over the years at ambient temperature, can function as an alternative to
blood transfusion for
resuscitation from
hemorrhagic shock and O2
therapeutics. Moreover, a recent study clarified beneficial effects for anti- oxidation and anti-
inflammation by
carbon monoxide (CO)-bound HbVs. Autoxidation of HbV (HbO2 → metHb + O2 -.) is unavoidable after
intravenous administration. Co-injection of
methylene blue can extract the intraerythrocytic glycolytic electron energy effectively and reduce metHb. Other
phenothiazine dyes can also function as electron mediators to improve the functional life span of HbV. This review paper summarizes recent progress of the research and development of HbV, aimed at clinical applications.